Sell-side analysts also estimate mean earnings per share for the year of $3.64, according to the report.
Financial analyst firms have given AmSurg an average price target of $83.63.
More articles on transactions and valuation issues:
Moody’s: Surgery Partners IPO filing is credit positive
SCA stock receives ‘hold’ rating
Q2 industry update: How did ASC companies fare?
